Patients with triple-negative breast cancer (TNBC) have the highest prevalence of gBRCA mutations (4.44% and 2.05% for BRCA1 and BRCA2, respectively) followed by those with hormone-receptor-negative disease (3% and 2.61% for BRCA1 and BRCA2, respectively) and hormone-receptor-positive disease (0.40% and 1.09% for BRCA1 and BRCA2, respectively) [6]. Here, BRCA1 is linked to triple-negative breast carcinoma.